ATE407950T1 - Löslicher interleukin-20 rezeptor - Google Patents

Löslicher interleukin-20 rezeptor

Info

Publication number
ATE407950T1
ATE407950T1 AT00986743T AT00986743T ATE407950T1 AT E407950 T1 ATE407950 T1 AT E407950T1 AT 00986743 T AT00986743 T AT 00986743T AT 00986743 T AT00986743 T AT 00986743T AT E407950 T1 ATE407950 T1 AT E407950T1
Authority
AT
Austria
Prior art keywords
receptor
soluble interleukin
immunoglobulin
subunit
fused
Prior art date
Application number
AT00986743T
Other languages
English (en)
Inventor
Donald Foster
Wenfeng Xu
Karen Madden
James Kelly
Cindy Sprecher
Cameron Brandt
Mark Rixon
Scott Presnell
Brian Fox
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE407950T1 publication Critical patent/ATE407950T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00986743T 1999-12-23 2000-12-22 Löslicher interleukin-20 rezeptor ATE407950T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47177499A 1999-12-23 1999-12-23
US21341600P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
ATE407950T1 true ATE407950T1 (de) 2008-09-15

Family

ID=26908064

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00986743T ATE407950T1 (de) 1999-12-23 2000-12-22 Löslicher interleukin-20 rezeptor
AT07012370T ATE485306T1 (de) 1999-12-23 2000-12-22 Löslicher interleukin-20-rezeptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07012370T ATE485306T1 (de) 1999-12-23 2000-12-22 Löslicher interleukin-20-rezeptor

Country Status (10)

Country Link
EP (2) EP1857466B1 (de)
JP (1) JP4741139B2 (de)
AT (2) ATE407950T1 (de)
AU (1) AU783473B2 (de)
CA (1) CA2395539C (de)
DE (2) DE60045139D1 (de)
DK (1) DK1246846T3 (de)
RU (1) RU2279441C2 (de)
UA (1) UA84830C2 (de)
WO (1) WO2001046232A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
PT1616575E (pt) * 1999-12-23 2012-08-07 Zymogenetics Inc Método para tratar inflamação
ATE407950T1 (de) 1999-12-23 2008-09-15 Zymogenetics Inc Löslicher interleukin-20 rezeptor
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
JP5015404B2 (ja) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
DK1351703T3 (da) 2000-09-15 2006-11-27 Zymogenetics Inc Anvendelse af et polypeptid omfattende det ekstracellulære domæne af IL-20RA og IL-20RB til behandling af inflammation
KR100628425B1 (ko) * 2001-06-20 2006-09-28 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
KR20050116390A (ko) 2003-03-24 2005-12-12 지모제넥틱스, 인코포레이티드 항-ｉｌ-20 항체 및 결합 파트너 그리고 염증에서의사용방법
WO2005014028A1 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
JP5020636B2 (ja) 2003-11-06 2012-09-05 シアトル ジェネティックス， インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
EP2286844A3 (de) 2004-06-01 2012-08-22 Genentech, Inc. Antikörper-Arzneimittelkonjugate und Verfahren
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
PT1812476E (pt) 2004-10-22 2010-11-08 Zymogenetics Inc Anticorpos anti-il-22ra e parceiros de ligação e métodos de utilização no tratamento de inflamações
EP2192132A3 (de) 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
CA2652304A1 (en) * 2006-05-17 2007-11-22 Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum Anti-inflammatory fusion protein
DK2340039T3 (en) * 2008-10-07 2016-02-29 Univ Nat Cheng Kung Use of IL-20 antagonists for treating osteoporosis
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
EP2538973A2 (de) 2010-02-26 2013-01-02 Novo Nordisk A/S Stabile, antikörperhaltige zusammensetzungen
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
CN102905692B (zh) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
CN103987407B (zh) 2011-10-14 2016-08-24 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其偶联物
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
EP2906297B1 (de) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
SI2906298T1 (sl) 2012-10-12 2018-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
JP6392764B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
WO2014057113A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
CN105189507A (zh) 2012-12-21 2015-12-23 斯皮罗根有限公司 吡咯并苯并二氮杂卓及其结合物
JP6527466B2 (ja) 2012-12-21 2019-06-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体
EP2968585B1 (de) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepine und konjugate davon
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (de) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3082875B1 (de) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetische verbindungen und antikörper-wirkstoff-konjugate davon
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
LT3151921T (lt) 2014-06-06 2019-12-10 Bristol Myers Squibb Co Antikūnai prieš gliukokortikoidu indukuojamą naviko nekrozės faktoriaus receptorių (gitr) ir jų panaudojimas
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP3388449A3 (de) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cystein-manipulierte antikörper und konjugate
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
CN113929770A (zh) 2014-11-21 2022-01-14 百时美施贵宝公司 包含修饰的重链恒定区的抗体
PE20170782A1 (es) 2014-11-21 2017-07-04 Bristol Myers Squibb Co Anticuerpos frente a cd73 y usos de los mismos
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US10690674B2 (en) 2015-06-03 2020-06-23 Bristol-Myers Squibb Company Anti-GITR antibodies for cancer diagnostics
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
EP3496763A1 (de) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
LT3544636T (lt) 2017-02-08 2021-06-25 Adc Therapeutics Sa Pirolobenzodiazepino-antikūno konjugatai
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HUE059828T2 (hu) 2017-04-18 2023-01-28 Medimmune Ltd Pirrolobenzodiazepin konjugátumok
EP3612234B1 (de) 2017-04-20 2024-03-13 ADC Therapeutics SA Kombinationstherapie mit anti-axl-antikörper-arzneimittel-konjugat
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
SG11202001907QA (en) 2017-09-20 2020-04-29 Ph Pharma Co Ltd Thailanstatin analogs
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
CA2296762A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
EP1424393A3 (de) 1997-11-26 2004-06-09 Zymogenetics Inc Cytokinähnliches Polypeptid-10 aus Säugetieren
PT1047781E (pt) * 1998-01-23 2004-11-30 Immunex Corp Receptores de il-18
JP2002505879A (ja) * 1998-03-09 2002-02-26 シェーリング コーポレイション ヒトレセプタータンパク質；関連する試薬および方法
PT1490386E (pt) * 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
WO1999061630A2 (en) * 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
AU4411699A (en) * 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Interferon receptor hkaef92
EP1141008A1 (de) * 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Cytokinin klasse ii rezeptor-ähnliche proteine und für diese kodierende nukleinsäuren
CA2383254A1 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE407950T1 (de) * 1999-12-23 2008-09-15 Zymogenetics Inc Löslicher interleukin-20 rezeptor
PT1616575E (pt) * 1999-12-23 2012-08-07 Zymogenetics Inc Método para tratar inflamação

Also Published As

Publication number Publication date
EP1246846B1 (de) 2008-09-10
EP1857466A2 (de) 2007-11-21
DE60045139D1 (de) 2010-12-02
RU2002119563A (ru) 2004-03-27
EP1246846A2 (de) 2002-10-09
DE60040240D1 (de) 2008-10-23
WO2001046232A2 (en) 2001-06-28
EP1857466A3 (de) 2008-02-13
JP4741139B2 (ja) 2011-08-03
CA2395539A1 (en) 2001-06-28
UA84830C2 (uk) 2008-12-10
CA2395539C (en) 2009-08-25
AU2292501A (en) 2001-07-03
DK1246846T3 (da) 2008-12-08
ATE485306T1 (de) 2010-11-15
WO2001046232A3 (en) 2002-02-21
EP1857466B1 (de) 2010-10-20
RU2279441C2 (ru) 2006-07-10
JP2003517846A (ja) 2003-06-03
AU783473B2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
DE60045139D1 (de) Löslicher Interleukin-20-Rezeptor
DE60232511D1 (de) Löslicher heterodimerer cytokinrezeptor
JP2003517846A5 (de)
DK1642972T3 (da) Terapeutisk anvendelse af BR43X2 opløselige receptorer
DK0640689T3 (da) p4-homodimer af interleukin-12.
IS5217A (is) Bræðsluprótín á föstu svæði úr beta-breytivaxtarþætti (TGF-beta) af gerð II og ónæmisglóbúlíni
ES542829A0 (es) Un metodo para evitar la formacion de un enlace de disulfuro en una proteina.
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
PT935607E (pt) Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes
LU91411I2 (fr) Panitumumab et ses dérivés pharmaceutiquement acceptables (VECTIBIX)
DK1621547T3 (da) Konjugater af polypeptidmolekyler og lipider fra malarie præ-erythrocytisk stadie
DE50114110D1 (de) Leuchte
IT1262898B (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk
EA200400384A1 (ru) Растворимый рецептор т-клетки
WO2001042294A3 (en) Clasp-4 transmembrane protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1246846

Country of ref document: EP